Skip to main content
All lobbying filings

Tiber Creek Group

Tiber Creek Group filed a Q3 report for Daiichi Sankyo, Inc. on October 20, 2025, reporting $50,000 in lobbying income.

Lobbying for Daiichi Sankyo, Inc. · Global pharmaceutical company.

As filed: TIBER CREEK GROUP for DAIICHI SANKYO, INC.

All filings by Tiber Creek Group · Everything Daiichi Sankyo, Inc. has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Income
$50,000
What the client paid this registrant for the period.
Client based in
New Jersey

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Health Issues

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Medicare/Medicaid

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).

 Bills named in this filing 3
  • H.R. 946
    ORPHAN Cures Act
  • S. 1862
    ORPHAN Cures Act
  • H.R. 4299
    Protecting Patient Access to Cancer and Complex Therapies Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem